Nyxoah (NYXH) Scheduled to Post Quarterly Earnings on Wednesday

Nyxoah (NASDAQ:NYXH) will be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Nyxoah to post earnings of ($0.46) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Tuesday, August 6th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). Nyxoah had a negative return on equity of 42.00% and a negative net margin of 908.32%. The firm had revenue of $0.83 million for the quarter, compared to the consensus estimate of $1.93 million. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Price Performance

Nyxoah stock opened at $9.44 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.16 and a current ratio of 5.47. The company’s 50-day moving average is $8.85 and its two-hundred day moving average is $8.81. Nyxoah has a 1 year low of $4.00 and a 1 year high of $20.00.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright decreased their price objective on Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, October 11th. Oppenheimer reduced their price objective on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald lowered their target price on shares of Nyxoah from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $17.00.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.